Xyntha (Hemophilia A and B)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 12
3.1.3 Prognosis and Quality of Life 14
3.2 Symptoms 16
3.2.1 Hemophilia A and B 16
3.2.2 Inhibitors 17
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Hemophilia A and B Diagnosis 19
4.1.2 Hemophilia A and B Treatment 19
4.1.3 Inhibitors Diagnosis 21
4.1.4 Inhibitors Treatment 21
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitive Assessment 24
6 Xyntha / ReFacto AF (moroctocog alfa) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Safety 30
6.4 SWOT Analysis 30
6.5 Forecast 30
7 Appendix 32
7.1 Bibliography 32
7.2 Abbreviations 34
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosed Hemophilia Patients 37
7.4.2 Percent Drug-Treated Patients 38
7.4.3 General Pricing Assumptions 38
7.4.4 Individual Drug Assumptions 39
7.5 Physicians and Specialists Included in this Study 40
7.6 About the Authors 42
7.6.1 Authors 42
7.6.2 Global Head of Healthcare 43
7.7 About GlobalData 44
7.8 Disclaimer 44